Is KPRX or GRCE more profitable?

Grace Therapeutics' return on equity of -36.11% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -63.38% -44.33% Grace Therapeutics N/A -36.11% -34.39%

Do analysts prefer RYM or KPRX?

Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 275.94%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is KPRX or VERU more profitable?

Veru's return on equity of -47.58% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -63.38% -44.33% Veru N/A -47.58% -35.83%

Kiora Pharmaceuticals (KPRX) Competitors

$2.66 +0.04 (+1.53%)

As of 04:00 PM Eastern

Compare

KPRX vs. GRCE, RYM, VERU, KPTI, and CPHI

Should you buy Kiora Pharmaceuticals stock or one of its competitors? Kiora Pharmaceuticals's main competitors and comparable companies include Grace Therapeutics (GRCE), RYTHM (RYM), Veru (VERU), Karyopharm Therapeutics (KPTI), and China Pharma (CPHI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by insiders. Comparatively, 10.8% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Grace Therapeutics' return on equity of -36.11% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Grace Therapeutics	N/A	-36.11%	-34.39%

Kiora Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the broader market. Comparatively, Grace Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market.

Kiora Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 275.94%. Grace Therapeutics has a consensus target price of $6.00, indicating a potential upside of 172.73%. Given Kiora Pharmaceuticals' higher possible upside, research analysts plainly believe Kiora Pharmaceuticals is more favorable than Grace Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Grace Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Grace Therapeutics had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 1 mentions for Grace Therapeutics and 0 mentions for Kiora Pharmaceuticals. Grace Therapeutics' average media sentiment score of 1.48 beat Kiora Pharmaceuticals' score of 0.00 indicating that Grace Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Grace Therapeutics	Positive

Grace Therapeutics has lower revenue, but higher earnings than Kiora Pharmaceuticals. Grace Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A
Grace Therapeutics	N/A	N/A	-$7.79M	-$1.18	N/A

Summary

Grace Therapeutics beats Kiora Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to RYTHM?

RYTHM (NASDAQ:RYM) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

In the previous week, RYTHM had 2 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 2 mentions for RYTHM and 0 mentions for Kiora Pharmaceuticals. RYTHM's average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
RYTHM	Neutral
Kiora Pharmaceuticals	Neutral

RYTHM has a beta of 9.47, meaning that its stock price is 847% more volatile than the broader market. Comparatively, Kiora Pharmaceuticals has a beta of -0.38, meaning that its stock price is 138% less volatile than the broader market.

Kiora Pharmaceuticals has lower revenue, but higher earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$51.01M	0.97	-$33.26M	-$10.53	N/A
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A

Kiora Pharmaceuticals has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%

Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 275.94%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Kiora Pharmaceuticals is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

6.0% of RYTHM shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 3.5% of RYTHM shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Kiora Pharmaceuticals beats RYTHM on 8 of the 15 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Veru?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Kiora Pharmaceuticals has higher earnings, but lower revenue than Veru. Veru is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A
Veru	$16.89M	2.67	-$22.73M	-$0.69	N/A

Kiora Pharmaceuticals has a beta of -0.38, indicating that its share price is 138% less volatile than the broader market. Comparatively, Veru has a beta of -1.15, indicating that its share price is 215% less volatile than the broader market.

Veru's return on equity of -47.58% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Veru	N/A	-47.58%	-35.83%

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Veru had 3 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 3 mentions for Veru and 0 mentions for Kiora Pharmaceuticals. Veru's average media sentiment score of 0.22 beat Kiora Pharmaceuticals' score of 0.00 indicating that Veru is being referred to more favorably in the news media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Veru	Neutral

Kiora Pharmaceuticals currently has a consensus target price of $10.00, indicating a potential upside of 275.94%. Veru has a consensus target price of $24.50, indicating a potential upside of 828.03%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Veru beats Kiora Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to Karyopharm Therapeutics?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Kiora Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 275.94%. Karyopharm Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 486.73%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kiora Pharmaceuticals has a beta of -0.38, suggesting that its share price is 138% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

In the previous week, Karyopharm Therapeutics had 4 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 4 mentions for Karyopharm Therapeutics and 0 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.09 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
Karyopharm Therapeutics	Neutral

Kiora Pharmaceuticals has higher earnings, but lower revenue than Karyopharm Therapeutics. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A
Karyopharm Therapeutics	$146.07M	0.30	-$196.04M	-$13.09	N/A

Kiora Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Summary

Karyopharm Therapeutics beats Kiora Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Kiora Pharmaceuticals compare to China Pharma?

Kiora Pharmaceuticals (NASDAQ:KPRX) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, Kiora Pharmaceuticals' average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Overall Sentiment
Kiora Pharmaceuticals	Neutral
China Pharma	Neutral

China Pharma has lower revenue, but higher earnings than Kiora Pharmaceuticals. China Pharma is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.73	-$10.84M	-$2.51	N/A
China Pharma	$3.91M	10.77	-$3.08M	-$0.43	N/A

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of China Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kiora Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 275.94%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Kiora Pharmaceuticals is more favorable than China Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Kiora Pharmaceuticals has a beta of -0.38, suggesting that its share price is 138% less volatile than the broader market. Comparatively, China Pharma has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Kiora Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Kiora Pharmaceuticals' return on equity of -63.38% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
China Pharma	-85.56%	-63.93%	-31.42%

Summary

Kiora Pharmaceuticals beats China Pharma on 8 of the 14 factors compared between the two stocks.

Get Kiora Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPRX vs. The Competition

Export

Metric	Kiora Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.76M	$12.46B	$7.29B	$12.82B
Dividend Yield	N/A	2.65%	2.54%	10.69%
P/E Ratio	-1.06	784.86	271.77	24.17
Price / Sales	0.73	790.77	596.17	78.70
Price / Cash	N/A	94.24	78.13	53.57
Price / Book	0.70	11.92	13.46	6.37
Net Income	-$10.84M	$2.80B	$3.46B	$347.61M
7 Day Performance	4.31%	2.19%	2.17%	0.00%
1 Month Performance	5.14%	3.12%	5.08%	2.06%
1 Year Performance	1.53%	8.35%	27.77%	20.56%

Kiora Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPRX Kiora Pharmaceuticals	2.1606 of 5 stars	$2.66 +1.5%	$10.00 +275.9%	-1.1%	$11.76M	$16.02M	N/A	10
GRCE Grace Therapeutics	2.1994 of 5 stars	$2.20 +3.3%	$6.00 +172.7%	-34.6%	$44.81M	N/A	N/A	N/A
RYM RYTHM	0.423 of 5 stars	$20.50 flat	N/A	N/A	$44.67M	$17.28M	N/A	140	Gap Up
VERU Veru	2.7686 of 5 stars	$2.64 +1.9%	$24.50 +828.0%	-26.9%	$44.16M	$16.89M	N/A	230	Analyst Downgrade
KPTI Karyopharm Therapeutics	2.788 of 5 stars	$2.00 +3.6%	$11.50 +475.0%	-72.0%	$43.78M	$146.07M	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPRX) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. GRCE, RYM, VERU, KPTI, and CPHI

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to RYTHM?

Summary

How does Kiora Pharmaceuticals compare to Veru?

Summary

How does Kiora Pharmaceuticals compare to Karyopharm Therapeutics?

Summary

How does Kiora Pharmaceuticals compare to China Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiora Pharmaceuticals (KPRX) Competitors

KPRX vs. GRCE, RYM, VERU, KPTI, and CPHI

How does Kiora Pharmaceuticals compare to Grace Therapeutics?

Do insiders & institutionals hold more shares of KPRX or GRCE?

Is KPRX or GRCE more profitable?

Which has more volatility and risk, KPRX or GRCE?

Do analysts prefer KPRX or GRCE?

Does the media prefer KPRX or GRCE?

Which has preferable valuation and earnings, KPRX or GRCE?

Summary

How does Kiora Pharmaceuticals compare to RYTHM?

Does the media refer more to RYM or KPRX?

Which has more risk & volatility, RYM or KPRX?

Which has higher earnings & valuation, RYM or KPRX?

Is RYM or KPRX more profitable?

Do analysts prefer RYM or KPRX?

Do institutionals and insiders believe in RYM or KPRX?

Summary

How does Kiora Pharmaceuticals compare to Veru?

Which has higher valuation and earnings, KPRX or VERU?

Which has more risk & volatility, KPRX or VERU?

Is KPRX or VERU more profitable?

Do institutionals & insiders believe in KPRX or VERU?

Does the media favor KPRX or VERU?

Do analysts recommend KPRX or VERU?

Summary

How does Kiora Pharmaceuticals compare to Karyopharm Therapeutics?

Do analysts recommend KPRX or KPTI?

Do insiders & institutionals have more ownership in KPRX or KPTI?

Which has more volatility & risk, KPRX or KPTI?

Does the media prefer KPRX or KPTI?

Which has better valuation & earnings, KPRX or KPTI?

Is KPRX or KPTI more profitable?

Summary

How does Kiora Pharmaceuticals compare to China Pharma?

Does the media favor KPRX or CPHI?

Which has preferable valuation & earnings, KPRX or CPHI?

Do insiders and institutionals have more ownership in KPRX or CPHI?

Do analysts rate KPRX or CPHI?

Which has more risk & volatility, KPRX or CPHI?

Is KPRX or CPHI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX vs. The Competition

Kiora Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools